Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:31am, Monday, 25'th Sep 2023
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The potential ripple effects of GLP-1 weight loss drugs like Ozempic and Wegovy are far-reaching. There could be reduced demand for junk food and increased demand for athletic brands.
3 Magnificent Growth Stocks to Buy Right Now
06:50am, Sunday, 24'th Sep 2023
Some might overlook AstraZeneca, but the stock has strong growth prospects. Eli Lilly continues to fire on all cylinders, with especially big opportunities for Mounjaro.
David vs. Goliath: 3 Stocks Poised to Challenge the ‘Magnificent 7′
04:00pm, Saturday, 23'rd Sep 2023
The so-called “Magnificent 7” stocks surged in 2023, contributing to a market rebound in an outsized manner. The stocks' presumed overrepresentation has investors considering other investments in
Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend
05:05pm, Friday, 22'nd Sep 2023
Biotech has long seemed to move slower than its fellow tech fields due to the complexity of biological systems and the difficulty of drug regulations. However, that precedent is set to change thanks t
Are Wall Street Analysts Wrong About Eli Lilly Stock?
09:45am, Friday, 22'nd Sep 2023
After massive gains this year, Eli Lilly's stock has eclipsed many analysts' price targets. Still, the drugmaker has huge growth potential from its current product lineup.
Eli Lilly, Boehringer Ingelheim's Jardiance gets FDA approval for chronic kidney disease
08:49am, Friday, 22'nd Sep 2023
Eli Lilly & Co. LLY, -3.42% and Boehringer Ingelheim said Friday that the U.S. Food and Drug Administration has approved their blockbuster drug Jardiance, already used for heart failure and diabetes,
Eli Lilly set to dominate obesity drug market into the next decade, analysts say
08:27am, Friday, 22'nd Sep 2023
Eli Lilly & Co. LLY, -3.42% is best positioned to dominate the fast-growing U.S. market for obesity drugs into the 2030s, BMO Capital Markets analysts said in a report late Thursday. Although Novo Nor
The 7 Most Hated Stocks by Institutional Traders
01:03pm, Wednesday, 20'th Sep 2023
While many retail investors are keen to discover which securities the big market players are snapping up, sometimes it's more telling to zero in on the stocks institutional traders are selling. Why? B
Eli Lilly Sues Businesses Over Alleged Sales of Fake Mounjaro Diabetes Drugs
11:40am, Wednesday, 20'th Sep 2023
Eli Lilly & Co. (LLY) sued 10 medical spas, wellness centers, and compounding pharmacies across the U.S. for allegedly selling products that fraudulently claimed to be its popular diabetes drug, Moun
Eli Lilly sues spas and pharmacies over bootlegged Mounjaro
08:02am, Wednesday, 20'th Sep 2023
Eli Lilly has taken legal action against spa owners, wellness centres and pharmacies for unauthorised versions of its best fat-busting drug Mounjaro. Four separate lawsuits have been filed against out
Flee to Healthcare Stocks if Recession Rears its Head?
07:04am, Wednesday, 20'th Sep 2023
If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.
Eli Lilly sues clinics allegedly selling knockoff versions of Mounjaro diabetes drug
04:33pm, Tuesday, 19'th Sep 2023
The lawsuits come as Eli Lilly grapples with a shortage of Mounjaro in the U.S. due to skyrocketing demand.
Eli Lilly sues over US sales of bogus Mounjaro for weight loss
03:06pm, Tuesday, 19'th Sep 2023
Eli Lilly on Tuesday said it was suing 10 U.S. medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, the active ingredient in its diabetes dru
Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?
07:06am, Tuesday, 19'th Sep 2023
Pharmaceutical giant Eli Lilly & Co. NYSE: LLY stock has been on a tear, trading up 57.7% year-to-date (YTD). The company is firing on all cylinders with its leading medications and a highly anticipat
